Michael Rowley

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

Vincenzo Summa, Alessia Petrocchi, Fabio Bonelli et al. · Journal of Medicinal Chemistry · 2008 · 634 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Discovery of 2-{4-[(3<i>S</i>)-Piperidin-3-yl]phenyl}-2<i>H</i>-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors

Philip Jones, Sergio Altamura, Julia K. Boueres et al. · Journal of Medicinal Chemistry · 2009 · 315 citations · Full text

Medicine, Oncology, Pharmacology +16

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

Vincenzo Summa, Steven W. Ludmerer, John A. McCauley et al. · Antimicrobial Agents and Chemotherapy · 2012 · 255 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +16

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

Steven J. Harper, John A. McCauley, Michael T. Rudd et al. · ACS Medicinal Chemistry Letters · 2012 · 201 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination

Philip Jones, Keith Wilcoxen, Michael Rowley et al. · Journal of Medicinal Chemistry · 2015 · 191 citations · Full text

Medicine, Oncology, Pharmacology +13